Peptides for body fat

A synergistic growth hormone releasing combination for body composition, sleep, and recovery.

• Increased lean muscle mass
• Reduced body fat
• Deeper, more restorative sleep

Synthetic analog of the first 29 amino acids of growth hormone–releasing hormone. Stimulates the pituitary to release endogenous GH in pulses, preserving the natural feedback loop and avoiding suppressed pituitary axis seen with exogenous HGH.

• Increased lean body mass
• Deeper sleep and improved REM
• Improved fat metabolism, especially visceral

Synthetic GHRH analog (modified GHRH 1-44) FDA-approved as Egrifta for HIV-associated lipodystrophy. Selectively reduces visceral adipose tissue and modestly elevates IGF-1 with a favorable safety profile relative to exogenous HGH.

• Visceral adipose tissue reduction
• Improved triglyceride and lipid profile
• Modest IGF-1 elevation

Recombinant DNA-derived 191-amino-acid growth hormone identical to endogenous human somatropin. FDA-approved for clinical GH deficiency (adult and pediatric); used off-label for body composition, recovery, and anti-aging. Direct hormone replacement — bypasses the pituitary axis (unlike Sermorelin/Tesamorelin).

• Increased lean body mass
• Visceral and subcutaneous fat loss
• Faster recovery from training and injury

Glycoprotein hormone produced during pregnancy. Mimics luteinizing hormone (LH), stimulating Leydig cells in the testes to produce testosterone and maintain testicular volume. Commonly co-administered with TRT to preserve fertility and prevent testicular atrophy, or used as a post-cycle/restart bridge.

• Testicular size preservation on TRT
• Maintains intratesticular testosterone
• Fertility preservation during exogenous testosterone use

Skytrofa is a once-weekly, long-acting growth hormone for children with growth hormone deficiency (GHD). Lonapegsomatropin is a prodrug that slowly releases somatropin (hGH) over 7 days, providing stable GH levels with a single weekly injection instead of daily shots.

• Linear growth acceleration in GH-deficient children
• Once-weekly convenience vs. daily injections
• Stable, sustained GH/IGF-1 levels throughout the week

Testosterone replacement therapy using a long-acting ester for stable hormone levels.

• Restored testosterone levels
• Improved energy and vitality
• Increased muscle mass and strength

A pan-agonist of the estrogen-related receptor (ERR) family — most potent at ERRα — described as an 'exercise mimetic.' Preclinical mouse studies show increased energy expenditure, fatty acid oxidation, and reduced fat mass accumulation.

• Activates aerobic exercise-like gene program (preclinical)
• Increases fatty acid oxidation in mice
• Increases energy expenditure in mice